Loading
A handful of ageing research reactors make most cancer isotopes. Coordinating their maintenance and funding reserve capacity would prevent the shortages that stop treatments.
Lutetium-177, iodine-131 and molybdenum-99 depend on a few research reactors (HFR Petten, BR2, MARIA, SAFARI-1, OPAL, several in Russia and the US), most over 50 years old. The OECD Nuclear Energy Agency's High-Level Group on Medical Radioisotopes coordinated molybdenum-99 after the 2009-10 crisis. The proposal is to extend that model formally to therapeutic isotopes: shared outage scheduling, an agreed reserve capacity margin funded by a per-dose levy, and public co-financing of the next generation of producers (PALLAS in the Netherlands, accelerator-based SHINE, new irradiation positions in existing reactors).
Shares Manufacturing cost and time for living and radioactive medicines, Radioligand therapy (beta emitters).
Shares Manufacturing cost and time for living and radioactive medicines, Radioligand therapy (beta emitters), Most of the world has almost no cancer care.
Shares Manufacturing cost and time for living and radioactive medicines, Radioligand therapy (beta emitters).
Shares Manufacturing cost and time for living and radioactive medicines, Radioligand therapy (beta emitters), Most of the world has almost no cancer care.
Shares Manufacturing cost and time for living and radioactive medicines, Most of the world has almost no cancer care.
Shares Manufacturing cost and time for living and radioactive medicines, Most of the world has almost no cancer care.
Shares Manufacturing cost and time for living and radioactive medicines, Radioligand therapy (beta emitters).
Shares Manufacturing cost and time for living and radioactive medicines, Most of the world has almost no cancer care.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/